Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi

Journal of Investigative Dermatology

Volumn 126, Issue 1, 2006, Pages 161-166

  Uribe, Pablo ^a   Andrade, Leonardo ^a   Gonzalez, Sergio ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN;

ARTICLE; CODON; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KNOWLEDGE; MAJOR CLINICAL STUDY; MELANOCYTIC NEVUS; MELANOMA; MOLECULAR MECHANICS; NEVUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SIGNAL TRANSDUCTION; VIRUS ONCOGENE;

CODON; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MUTATION; NEVUS, PIGMENTED; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 33644775655     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700011     Document Type: Article

References (31)

1. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J et al. (2001) Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61:6500-10
2. Arbiser JL (2003) Activation of B-raf in non-malignant nevi predicts a novel tumor suppressor gene in melanoma (MAP kinase phosphatase). J Invest Dermatol 121(5):xiv
3. Arbiser JL, Weiss SW, Arbiser ZK, Bravo F, Govindarajan B, Caceres-Rios H et al. (2001) Differential expression of active mitogen-activated protein kinase in cutaneous endothelial neoplasms: implications for biologic behavior and response to therapy. J Am Acad Dermatol 44:193-7
4. Brondello JM, Brunet A, Pouyssegur J, McKenzie FR (1997) The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. J Biol Chem 272:1368-76
5. Clark Jr WH, Elder DE, Guerry DT, Epstein MN, Greene MH, Van Horn M (1984) A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 15:1147-65
6. Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, Cotsonis G et al. (2002) Mitogen-activated protein kinase activation is an early event in melanoma progression. Clin Cancer Res 8:3728-33
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-54
8. Duray PH, Ernstoff MS (1987) Dysplastic nevus in histologic contiguity with acquired nonfamilial melanoma. Chnicopathologic experience in a 100-bed hospital. Arch Dermatol 123:80-4
9. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS et al. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273:18623-32
10. Gioeli D, Mandell JW, Petroni GR, Frierson Jr HF, Weber MJ (1999) Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59:279-84
11. Govindarajan B, Bai X, Cohen C, Zhong H, Kihroy S, Louis G et al. (2003) Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem 278:9790-5
12. Hahn WC, Weinberg RA (2002) Rules for making human tumor cells. N Engl J Med 347:1593-603
13. Hindley A, Kolch W (2002) Extracellular signal regulated kitiase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. J Cell Sci 115:1575-81
14. Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T et al. (2003) Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 63:8132-7
15. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics, 2003. CA Cancer J Clin 53:5-26
16. Jorgensen K, Holm R, Maelandsmo GM, Florenes VA (2003) Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome. Clin Cancer Res 9:5325-31
17. Kumar R, Angelini S, Snellman E, Hemminki K (2004) BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 122:342-8
18. Miller CJ, Cheung M, Sharma A, Clarke L, Helm K, Mauger D et al. (2004) Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol 123:990-2
19. Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, Hansson J (2002) Screening of N-ras Codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res 8:3468-74
20. Peyssonnaux C, Eychene A (2001) The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93:53-62
21. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM et al. (2003) High frequency of BRAF mutations in nevi. Nat Genet 33:19-20
22. Pollock PM, Trent JM (2000) The genetics of cutaneous melanoma. Clin Lab Med 20:667-90
23. Polsky D, Cordon-Cardo C, Boughton A (2001) Molecular biology of melanoma. In: The Molecular Basis of Cancer. (Liotta LA, ed), Philadelphia: Saunders, 385-404
24. Rhodes AR, Harrist TJ, Day CL, Mihm Jr MC, Fitzpatrick TB, Sober AJ (1983) Dysplastic melanocytic nevi in histologic association with 234 primary cutaneous melanomas. J Am Acad Dermatol 9:563-74
25. Saldanha G, Purnell D, Fletcher A, Potter L, Gillies A, Pringle JH (2004) High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer 111:705-10
26. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL et al. (2003) Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63:756-9
27. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK (2004) Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 64:5186-92
28. Sober AJ, Burstein JM (1995) Precursors to skin cancer. Cancer 75:645-650
29. Uribe P, Wistuba II, Gonzalez S (2003) BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 25:365-70
30. Wan PT, Gamett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-67
31. Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D et al. (2004) V599EB-RAF is an oncogene in melaaocytes. Cancer Res 64:2338-42